LETTER FROM THE CHAIRMAN AND CEO OF SYNAIRGEN LIMITED
(Incorporated in England and Wales with Registered No. 05233429)
Directors: Mark Parry-Billings (Executive Chairman) | Registered Office: Mailpoint 810, Level F, South Block |
To all Shareholders
31 July 2026
Corporate Update
Dear Shareholders,
Further to the update to shareholders of 7 July 2026, Synairgen Limited (the “Company”), a clinical-stage biotechnology company with the sole asset SNG001 (inhaled interferon beta), today wishes to update further shareholders as to the progress of the orderly wind-down of operations, and preparations for a Members’ Voluntary Liquidation (“MVL”)
Wind-down of operations
All activities are progressing in line with expectations, including those relating to the closure of the phase 2 INVENT clinical study, non-clinical R&D, Company facilities, staffing, and finance (as outlined in the corporate update of 30 April).
Members’ Voluntary Liquidation (MVL)
As indicated in the corporate update of 7 July 2026, we would like to share the following indicative timetable of this process:
By end of August 2026:
- Liquidation Circular issued including shareholder resolution, notification of general meeting and Form of Proxy
During September 2026:
- General meeting held
- MVL process formally commences following receipt of requisite shareholder approvals
By October 2026:
- First interim distribution of liquidation funds to shareholders
In first half 2027:
- Final distribution of residual liquidation funds to shareholders
The Company currently anticipates that funds in excess of £5 million will be distributed to shareholders in total from both the initial and final tranches. The amount being dependent on finalisation of matters relating to the wind-down of the Company and professional fees associated with the MVL process. Further detail will be provided in the Liquidation Circular which is expected to be issued by the end of August 2026.
In closing, we would wish to sincerely acknowledge again all shareholders during this challenging wind-down period.
Yours sincerely
Mark Parry-Billings | Joseph Colliver |
For further enquiries, please contact:
Synairgen Limited
+ 44 (0)23 8051 2800
info@synairgen.com
For more information about Synairgen, please see www.synairgen.com